AzTrials
AzTrials

Colitis, UlcerativeINTENTNCT03532932

A Study to Evaluate Disease Control and Treatment Pattern in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD) in Real Life Practice

An observational study of Colitis, Ulcerative and Crohn Disease, run by Takeda at 36 sites in 3 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to characterize the treatment patterns associated with biologics agents use or non-biological therapy in participants with moderate to severe Ulcerative Colitis (UC) and Crohn's Disease (CD). Read more about this study

Who is it for?
Ages 18 years and older
How many people
1,990 participants
Where
36 sitesin 3 countries
Study dates
20 Jul 2018to 8 Nov 2021
Phase
Observational
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Participants diagnosed with moderate to severe UC or CD will be observed both retrospectively and prospectively.

Who may be able to join

  • Has confirmed diagnosis of CD or UC for at least 2 years prior to enrollment in the study.
  • Has a moderate to severe IBD flare at the time of enrollment or in participant anamnesis within 2 years before enrollment treated with steroids or/ and immunosuppressive agents or/ and biologic therapy. IBD flare(s) must be confirmed in the source documentation.
  • Current treatment with steroids or/ and immunosuppressive agents or/ and 5-aminosalicylate (ASA) or/ and biologic therapy.

Who cannot join

  • Current or previous (within the last two years) indeterminate or not classified colitis.
  • Changing of IBD type in anamnesis (that is, from UC to CD, etc) within the last two years.
  • Current, previous (within the last two years) or planned (for the next one year) participation in interventional clinical trial.
  • Presenting of mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
  • Has received previous treatment with biologic therapy/immunosuppressive agents for conditions other than IBD ever in their lifetime.

Trial locations and contacts

36 sites in 3 countries.

36 sites in 3 countries

Russia31 sites
  • Regional Clinical Hospital

    Barnaul, Altai Territory, 656024

  • State Budgetary Healthcare Institution "Chelyabinsk Regional Clinical hospital"

    Chelyabinsk, Chelyabinsk Oblast, 454076

  • Federal State Budgetary Educational Institution of Higher Education "Chita state medical academy" of the Ministry of Health of the Russian Federation

    Chita, Zabaykalskiy (Transbaikal) Kray, 672000

  • State Budgetary Healthcare Institution Irkutsk Order of the Badge of Honor Regional Clinical Hospital

    Irkutsk, Irkutsk Oblast, 664049

  • Budgetary Institution of Health in the Republic of Udmurtia First Republican Clinical Hospital under the Ministry of Health, the Republic of Udmurtia

    Izhevsk, Udmurtiya Republic, 426039

  • Republican Clinical Hospital Ministry of health Republic of Tatarstan

    Kazan', Tatarstan Republic, 20064

  • State Autonomous Healthcare Institution of Kemerovo region "Kemerovo regional clinical hospital n. a. S.V. Belyaev"

    Kemerovo, Kemerovo Oblast, 650066

  • Regional State Budgetary Healthcare Institution "Regional Clinical Hospital # 1 n. a. S.I. Sergeev"

    Khabarovsk, Khabarovsk Territory, 680009

  • State Budgetary Institution "Regional Clinical Hospital No. 1 named after Professor S.V. Ochapovsky".

    Krasnodar, Krasnodarskiy Kray, 350086

  • MEDSI Clinical Hospital

    Krasnogorsk, Moscow Oblast, 150062

  • Krasnoyarsk Interdistrict Clinical Hospital No. 20 named after IS Berzon

    Krasnoyarsk, Krasnoyarsk Region, 660123

  • Moscow Clinical Scientific Center

    Moscow, Moscow Oblast, 111123

  • State Scientific Center of Coloproctology

    Moscow, Moscow Oblast, 123423

  • State Budgetary Healthcare Institution Moscow Regional Research and Clinical Institute (MONIKI) n. a. M. F. Vladimirskiy

    Moscow, Moscow Oblast, 129110

  • Regional Clinical Hospital

    Omsk, Omsk Oblast, 644111

  • Perm regional clinical hospital

    Perm, Perm Krai, 614990

  • Federal State Budget Educational Institution of Higher Education "Petrozavodsk State University"

    Petrozavodsk, Republic of Karelia, 185910

  • State Budgetary Institution of Ryazan Region "City Clinical Hospital #4"

    Ryazan, Ryazan Oblast, 390023

  • Federal State Budget Military Educational Institution of Higher Education "Military Medical Academy named after S.Kirov" of the Ministry of Defense of the Russian Federation

    Saint-Petersburg, Leningradskaya Oblast', 194044

  • Scientific and Research Center "Eco-safety", LLC

    Saint-Petersburg, Leningradskaya Oblast', 196143

  • St. Petersburg State Budgetary Healthcare Institution "City Clinical Hospital No. 31"

    Saint-Petersburg, Leningradskaya Oblast', 197110

  • Medical Academy n. a. S. I. Georgievksiy Federal State Autonomous Educational Institution of Higher Education "Crimean State University n. a. V.I. Vernadskiy

    Simferopol, Republic Crimea, 295007

  • State Budgetary Healthcare Institution Republic of Crimea "Republican clinical hospital n.a. N.A.Semashko"

    Simferopol, Republic Crimea, 295017

  • Budgetary Institution "Surgut District Clinical Hospital"

    Surgut, Khanty-Mansi Autonomous Okrug-Yugra, 628408

  • Federal State Budgetary Educational Institution of Higher Education "Bashkir State Medical University" of the Ministry of Health of the Russian Federation

    Ufa, Bashkortostan Republic, 450008

  • State Budgetary Healthcare Institution RB Regional Clinical Hospital G.G Kuvatov

    Ufa, Ufa Region, 450005

  • State Budgetary Healthcare Institution City Clinical Hospital 21

    Ufa, Ufa Region, 450071

  • State Healthcare Institution Ulyanovsk Regional Clinical Hospital

    Ulyanovsk, Ulyanovsk Oblast, 432017

  • Regional Clinical Hospital

    Vladimir, Vladimirskaya Oblast’, 600023

  • Society with limited liability "Medical Association" New Hospital "

    Yekaterinburg, Sverdlovsk Oblast, 620109

  • Health Care Unit # 1 of Yoshkar-Ola city

    Yoshkar-Ola, Republic of Maruy El, 424037

Other trials in Russia

Kazakhstan3 sites
  • Scientific-Research Institute of Cardiology and Internal Diseases, Gastroentorology department

    Almaty, Almaty Region, 050000

  • The Centre of Coloproctology based at City Hospital 1

    Astana, Astana, 010000

  • Regional clinical hospital

    Shymkent, Shymkent, 160000

Other trials in Kazakhstan

Belarus2 sites
  • Republican Gastroenterology Center, City Clinical Hospital # 10

    Minsk, Minsk Oblast, 220077

  • Vitebsk regional clinical specialized center

    Vitebsk, Vitebsk Oblast, 210601

Other trials in Belarus

About this study

Official title: International, Multicentre, Non-Interventional Study To Evaluate Disease Control And Treatment Pattern In Patients With Moderate To Severe Inflammatory Bowel Disease In Real Life Practice

The purpose of this study is to characterize the treatment patterns associated with biologics agents use or non-biological therapy in participants with moderate to severe Ulcerative Colitis (UC) and Crohn's Disease (CD).

Read the detailed description

This is a non-interventional, retrospective and prospective study of participants with IBD. This study will collect data to provide accurate and comprehensive information related to treatment patterns associated with biologics use or non-biological therapy in participants with moderate to severe UC and CD in routine clinical practice.

The study will have retrospective data collection from past records of participants within the last 2 years before participant's enrollment. The prospective part of the study will include one year of observation and data collection after the participant's enrollment in the study.

The study will enroll approximately 2000 participants. Participants will be enrolled in one of the two groups:

  • UC Participants
  • CD Participants

This multi-center trial will be conducted in Russia, Belarus and Kazakhstan. The overall period of observation in this study will be approximately 12 months. Participants will make 2 visits within their routine practice to the clinic after the enrollment into the study including a final visit at Month 12.

Keywords
Drug therapy
Medical subject headings
Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT03532932
Study groupRoleWhat they receive
UC ParticipantsParticipants diagnosed with moderate to severe UC from approximately 35 investigational sites will be observed retrospectively for previous 2 years before enrollment until Visit 1 and will be observed prospectively for 1 year after participant's enrollment into the study to assess treatment patterns and treatment outcomes in UC participants particularly on the use of available biological therapies.
CD ParticipantsParticipants diagnosed with moderate to severe CD from approximately 35 investigational sites will be observed retrospectively for previous 2 years before enrollment until Visit 1 and will be observed prospectively for 1 year after participant's enrollment into the study to assess treatment patterns and treatment outcomes in CD participants particularly on the use of available biological therapies.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants Stratified by Treatment Patterns Associated With Biologics Agents Use or Non-biological Therapy in Participants With Moderate to Severe UC and CD

    Treatment pattern with biologics agents or non-biological therapy included unique treatments combinations, Like>5-ASA1(Start with 5-ASA:5-ASA→Systemic biologics [SB] +/- STER+/-standard therapy[ST]),>5ASA2(without [w/o] STER),>5ASA3(5-ASA→STER+/-ST),>5ASA4(5-ASA→IS),>5ASA 5(5-ASA→5-ASA+/-IS),>5ASA6(5-ASA→ NOTR),>5ASA7(5-ASA),>NOTR1(NOTR→Biologics [BIO]+/-ST+/-STER),>NOTR 2(TR→ST+/-STER),>NOTR 3(NOTR),>IS1(IS→SB+STER+/-ST),>IS2(IS→SB+ST w/o STER),>IS 3(IS→STER+/-ST),>IS4(IS→5-ASA),>IS5(IS→NOTR),>IS6(IS→5-ASA+IS),>IS7(IS mono),>IS+5ASA1(IS+5-ASA→SB +/-ST),>IS+5ASA2(IS+5-ASA→SB ±ST w/o STER),>IS+5ASA3(IS+5-ASA→STER+/-ST),>IS+5ASA4(IS+5-ASA→NOTR),>IS+5ASA5(IS+5-ASA→IS),>IS+5ASA6(IS+5-ASA→5-ASA),>IS+5ASA7(IS+5-ASA),>BIO1(SB+/-STER+/-ST→withdrawal [w/d] of SB+ST+/-STER),>BIO2(SB+/-STER+/-ST),>BIO3(SB+/-STER+/-ST→NOTR),>BIO4(SB+/-STER+/-ST→SB mono),>STER1(STER+/-ST→w/d of STER+SB+/-ST),>STER2(STER+/-ST→w/d of STER+ST),>STER3(STER+/-ST→SB+STER+/-ST),>STER4(STER+/-ST→NOTR),>STER5(STER+/-ST).

    Measured: From 2 years before enrollment up to Month 12 after enrollment (up to 3 years)

Secondary outcomes (12)
  1. Number of Participants Stratified by Location of Disease

    Measured: Within 1 year prior to Baseline (Visit 1)

  2. Number of Participants Stratified by Disease Severity

    Disease Severity was defined using Harvey-Bradshaw Index (HBI) and mayo index. HBI is validated clinical index for evaluation of CD disease severity, including the 5 categories: general well-being, abdominal pain, number of liquid stools, abdominal mass and complications. The score ranges from 0 to 25, where score less than (<) 5 was remission, score 5-7 was mild activity, score 8-16 was moderate, and score >16 was severe. Mayo index was used for evaluation of UC disease severity. Mayo index is an instrument consisting of 4 categories of: stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment, each sub score graded from 0 to 3. The score ranges from 0 to 12, where score <2 was remission, score 3-5 was mild, score 6-10 was moderate, and score >10 was severe.

    Measured: At Visit 1 (Baseline), Visit 2 (6 months), Visit 3 (12 months) of prospective period

  3. Number of Participants Based on Usage of Methods for Documentation of Disease Activity in Routine Practice

    Disease activity assessment was performed using following methods- biomarkers, endoscopy, biopsy, X-ray, magnetic resonance imaging (MRI) and ultrasound examination. Number of participants whose disease activity was evaluated using the respective methods were reported.

    Measured: From Baseline Visit (Day 1) up to 12 months

  4. Number of Assessments Using Different Methods in Participants With UC and CD Disease Activity

    Disease activity assessment was performed using following methods- biomarkers, endoscopy, biopsy, X-ray, MRI and ultrasound examination. Biomarkers was based on evaluation of C-reactive protein (CRP) and/or fecal calprotectin levels. Endoscopy included colonoscopy/rectoromanoscopy/sigmoidoscopy and/or video capsule endoscopy and/or esophagogastroduodenoscopy (in the presence or suspicion of the presence of lesions of the upper gastrointestinal tract in Crohn's disease), X-ray was used for examination of the intestine to exclude stricturing and other lesions, MRI was used for examination of the intestine to exclude stricturing and other lesions using MRI and ultrasound for examination of the intestine to exclude stricturing and other lesions. Number of assessments using different methods in participants with UC and CD disease activity was summarized for specified methods and reported in terms of mean and standard deviation.

    Measured: From Baseline Visit (Day 1) up to 12 months

  5. UC Participants: Percentage of Participants Who Achieved Combined Clinical and Endoscopic Remission Based on Mayo Index

    The full Mayo index is an instrument to measure disease activity of UC. It consists of 4 parameters: stool frequency, rectal bleeding, endoscopic evaluation, and Physician's global assessment. Each parameter of the score ranged from 0 (normal or inactive disease) to 3 (severe activity). The score ranged from 0 to 12, where score <2 was remission, score 3-5 was mild activity, score 6-10 was moderate activity, and score >10 was severe activity. Higher scores indicating higher disease activity.

    Measured: At Visit 1 (Baseline), Visit 2 (6 months), Visit 3 (12 months) of prospective period

  6. CD Participants: Percentage of Participants Who Achieved Clinical Remission Based on HBI

    HBI was used for evaluation of CD remission. It is a validated clinical index for CD, including the 5 categories of: general well-being, abdominal pain, number of liquid stools, abdominal mass and complications. The score ranges from 0 to 25, where score <5 was remission, score 5-7 was mild activity, score 8-16 was moderate activity, and score >16 was severe activity. Higher scores indicating higher disease activity.

    Measured: At Visit 1 (Baseline), Visit 2 (6 months), Visit 3 (12 months) of prospective period

  7. Number of Participants With at Least One Episode of Failure of Biological or Non-biological Therapy

    Measured: From 2 years before enrollment up to Month 12 after enrollment (up to 3 years)

  8. Number of Participants Who Needed Treatment Adjustments Based on Disease Activity Assessment

    Measured: From 2 years before enrollment up to Month 12 after enrollment (up to 3 years)

  9. Percentage of Participants Stratified by Achieving the Treatment Goals

    Treat to target (T2T) approach was used for assessment of treatment goals. A "Treat to target" approach for UC included clinical remission (defined as resolution of rectal bleeding and diarrhea/altered bowel habit) and endoscopic remission (defined as Mayo endoscopic subscore of 0-1). Biomarker remission (normal C-reactive protein [CRP] and calprotectin) was considered as an adjunctive target. Histological remission was considered as an adjunctive goal. Clinical remission for CD was defined as resolution of abdominal pain and diarrhea/altered bowel habit. Endoscopic remission for CD was defined as resolution of ulceration at ileocolonoscopy or resolution of findings of inflammation on cross-sectional imaging in participants who cannot be adequately assessed with ileocolonoscopy. Biomarker remission (normal CRP and faecal calprotectin) was considered as an adjunctive target.

    Measured: From 2 years before enrollment up to Month 12 after enrollment (up to 3 years)

  10. Percentage of Participants Based on Challenges of Implementing a T2T Strategy in UC and CD Participants in Real Clinical Practice

    "Other" challenges included absence or inaccessibility of MRI (technical problems), participants financial difficulties, disability and bureaucratic problems, unavailability of biotherapy, limited quotas, referral of participants to other centers, absence of biotherapy treatment quotas, difficulty in performing computed tomography (CT).

    Measured: From 2 years before enrollment up to Month 12 after enrollment (up to 3 years)

  11. Percentage of Participants Based on Hospitalizations Due to Complications, IBD Related Surgeries, and Disability Determination in Participants With Moderate to Severe UC and CD

    Measured: From 2 years before enrollment up to Month 12 after enrollment (up to 3 years)

  12. Percentage of Participants Based on Surgical Treatment by Indications and Type of Surgeries

    Indications for surgical treatment included aggravation, intestinal bleeding, colon perforation, internal fistulas, abdominal cavity infiltrate, Interintestinal or Intraabdominal abscess, strictures in the gastrointestinal tract, anal fissures, and other. Types of surgeries includes both emergency and planned.

    Measured: From 2 years before enrollment up to Month 12 after enrollment (up to 3 years)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 May 2018
  2. Study start20 Jul 2018
  3. Primary completion8 Nov 2021
  4. Study completion8 Nov 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
1,990 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03532932
Sponsor's protocol ID
IBD-5005
Other IDs
U1111-1207-6263
Acronym
INTENT
Status last verified
Sep 2023
First submitted
1 May 2018
Last updated
29 Mar 2024
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Questions about this trial

What is this clinical trial studying?

An observational study of Colitis, Ulcerative and Crohn Disease, run by Takeda at 36 sites in 3 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 36 sites in Russia, Kazakhstan, Belarus. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 29 Mar 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants Stratified by Treatment Patterns Associated With Biologics Agents Use or Non-biological Therapy in Participants With Moderate to Severe UC and CD (time frame: From 2 years before enrollment up to Month 12 after enrollment (up to 3 years)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Mar 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in